Thalassemia Major

Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital

Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital

prevalence of malnutrition among thalassemic children attending assiut university children hospital

determination of the most common causes responsible for poor growth seen in thalassemic patients

decrease morbidity by providing possible strategies for early prevention of the problem of poor growth occurring in patients with thalassemia major

ARAbdelmonem

resident doctor of pediatrics

Assiut University

Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.
The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding.

Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.
Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.
Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered.

Postoperative Nausea and Vomiting

Sugammadex

Neostigmine

KK Women's and Children's Hospital

Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery

Comparison of Sugammadex Versus Neostigmine in Women at High Risk of Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery: A Randomized Controlled Trial

Incidence of self-reported, postoperative nausea at 24-hours after neuromuscular blockade reversal with sugammadex or neostigmine, in women at high-risk of PONV, after undergoing laparoscopic gynaecological surgery.

Incidence of self-reported PONV following administration of Sugammadex or Neostigmine reversal for neuromuscular blockade 6-hours following laparoscopic gynaecological surgery in women at high-risk of PONV.

Severity of self-reported PONV after administration of Sugammadex or Neostigmine for neuromuscular blockade reversal at 6-hours and 24-hours after undergoing laparoscopic gynaecological surgery in women at high-risk of PONV.

Pain intensity after administration of Sugammadex or Neostigmine for neuromuscular blockade reversal in women at high-risk for PONV at 6-hours and 24-hours following laparoscopic gynaecological surgery.

Quality of recovery score after administration of Sugammadex or Neostigmine for neuromuscular blockade reversal in women at high-risk of PONV at 24 hours following laparoscopic gynaecological surgery.

Deepak Mathur

Consultant Anaesthetist

Singhealth Foundation

Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)

Acute Mountain Sickness

Erythropoietin

Soon Bae Kim, M.D., Ph.D.

Erythropoietin in the Prevention of Acute Mountain Sickness

Randomized, Controlled Trial of Erythropoietin in the Prevention of Acute Mountain Sickness

The AMS self-report score is the sum of answers to five questions (headache; gastrointestinal symptoms (anorexia, nausea, or vomiting); fatigue or weakness; dizziness or lightheadedness; difficulty sleeping) rating from 0 to 3.

High altitude cerebral edema 1) Mental confusion 2) Ataxia 3) Severe lassitude
Moderate high altitude pulmonary edema 1) Symptoms of dyspnea, weakness, fatigue with mild exertion 2) Cannot perform light activity 3) Headache with cough, dyspnea at rest 4) Heartbeats per min: 110-120 5) Breaths per min: 20-30
Severe AMS: LLS >8

Soon Bae Kim, M.D., PhD.

Professor of Medicine

University of Ulsan

HK inno.N Corporation

This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.

Solid Tumors

Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.

Pazopanib and TH-302

Duke Cancer Institute

Dose Escalation Study of Pazopanib Plus TH-302

Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors

To define the maximal tolerated dose (if any) and the recommended phase II doses for the combination of pazopanib plus TH-302 in patients with advanced solid tumors

To describe any dose limiting and non dose-limiting toxicities of this drug combination

anorexia/hypoxia

Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital

Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery

Erythropoietin in the Prevention of Acute Mountain Sickness

Dose Escalation Study of Pazopanib Plus TH-302

Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort

Den mest komplette database med medicinske urter understøttet af videnskab